<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75571">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936844</url>
  </required_header>
  <id_info>
    <org_study_id>VCU HM15347</org_study_id>
    <nct_id>NCT01936844</nct_id>
  </id_info>
  <brief_title>IL-1 Blockade in Acute Heart Failure</brief_title>
  <acronym>Anakinra ADHF</acronym>
  <official_title>Interleukin-1 Blockade in Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Anakinra ADHF Data Safety and Monitoring Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human
      interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart
      failure with the aim to quench the acute inflammatory response, as measured by the
      area-under-the-curve for C reactive protein over 14 days.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>C reactive protein</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>The area-under-the-curve for plasma C reactive protein (CRP) levels measured at admission and then on day 2, 3, 4, 5 and 14.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo-corrected interval change in left ventricular ejection fraction (LVEF) between admission and 14 day follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brachial artery vasoreactivity</measure>
    <time_frame>3 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Placebo-corrected interval changed in flow mediated vasodilatation of the brachial artery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Anakinra (short)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo injections twice daily for the first 3 days then once daily for days 4-14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (high dose)</intervention_name>
    <description>Anakinra 100 mg daily twice daily for days 1, 2 and 3</description>
    <arm_group_label>Anakinra (short)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra (standard dose)</intervention_name>
    <description>Anakinra 100 mg daily for days 4-14</description>
    <arm_group_label>Anakinra (short)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All 5 criteria need to be met for enrollment of the patient in the study

          1. Primary diagnosis of acute decompensated heart failure within the last 24 hours as
             evidenced by BOTH of the following:

               1. dyspnea or respiratory distress or tachypnea at rest or with minimal exertion

               2. evidence of elevated cardiac filling pressure or pulmonary congestion (at least
                  one of the conditions must be met);

             i. pulmonary congestion/edema at physical exam OR chest XRay; ii. plasma BNP levels
             ≥200 pg/mL; iii.invasive measurement of left ventricular end-diastolic pressure &gt;18
             mmHg or of pulmonary artery occluding pressure (wedge) &gt;16 mmHg.

          2. Left ventricular systolic dysfunction (LVEF&lt;40%) during index hospitalization or
             prior 12 months.

          3. Age ≥18 years old

          4. Willing and able to provide written informed consent.

          5. Screening plasma C-reactive protein levels &gt;5 mg/L.

        Exclusion Criteria Subjects will not be eligible if they meet any of the following 15
        exclusion criteria.

          1. The primary diagnosis for admission is NOT decompensated heart failure, including
             diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or
             brady-arrhythmias.

          2. Concomitant clinically significant comorbidities that would interfere with the
             execution or interpretation of the study including but not limited to acute coronary
             syndromes, uncontrolled hypertention or orthostatic hypotension, tachy- or
             brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders
             affecting respiration.

          3. Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT),
             coronary artery revascularization procedures, or heart valve surgeries.

          4. Previous or planned implantation of left ventricular assist devices or
             heart-transplant.

          5. Chronic use of intravenous inotropes.

          6. Recent (&lt;14 days) use of immunosuppressive or anti-inflammatory drugs (not including
             NSAIDs).

          7. Chronic inflammatory disorder (including but not limited to rheumatoid arthritis,
             systemic lupus erythematosus).

          8. Active infection (of any type);

          9. Chronic/recurrent infectious disease (including HBV, HCV, and HIV/AIDS).

         10. Prior (within the past 10 years) or current malignancy.

         11. Any comorbidity limiting survival or ability to complete the study.

         12. End stage kidney disease requiring renal replacement therapy.

         13. Neutropenia (&lt;2,000/mm3) or Thrombocytopenia (&lt;50,000/mm3).

         14. Pregnancy.

         15. Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion
             during cardiopulmonary exercise testing obtained during the baseline testing.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Benjamin W Van Tassell, PharmD</last_name>
    <phone>804-8284583</phone>
    <email>bvantassell@vcu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio Abbate, MD, PhD</last_name>
    <phone>804-8280513</phone>
    <email>aabbate@vcu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin W Van Tassell, PharmD</last_name>
      <phone>804-828-4583</phone>
      <email>bvantassell@vcu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Abbate, MD, PhD</last_name>
      <phone>804-828-0513</phone>
      <email>aabbate@vcu.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>September 3, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
